Relación entre el fármaco semaglutida y la reducción de peso en pacientes con obesidad: una revisión sistemática / Relation between the drug semaglutide and weight reduction in patients with obesity: a systematic review / Relação entre a droga semaglutida e a perda de peso em pacientes obesos: uma revisão sistemática

El tratamiento farmacológico para la obesidad es muy limitado, entre los existentes en el mercado, destaca la Semaglutida, ampolla subcutánea que se aplica semanalmente y se usa en pacientes con diabetes y obesidad. OBJETIVO: establecer la relación de Semaglutida como un potencial fármaco para el tratamiento de obesidad. MÉTODO: estudio de tipo descriptivo, principalmente enfocado en la revisión y análisis de investigaciones publicadas en bases de datos científicas de alta relevancia, restringiéndose únicamente a publicaciones del 2015 en adelante (2022) que engloben como tópico principal el uso de Semaglutida. RESULTADO: se identificaron 802 registros en las bases de datos, aplicando los criterios de selección se identificaron 45 artículos como potenciales fuentes de información, finalmente se seleccionaron 15 artículos con datos altamente relevantes para esta revisión, donde se consideró la dosis del fármaco para la reducción de peso se observa que a mayor cantidad de Semaglutida se obtiene una reducción significativa de peso, llegando a una media de 11.82 kg. CONCLUSIÓN: el tratamiento semanal con Semaglutida administrada a nivel subcutánea con cambios en el estilo de alimentación y actividad física, dan como resultados pérdida de peso sostenida en el tiempo clínicamente relevante, pudiendo llegar a la aplicabilidad en pacientes cuyo tratamiento por otros métodos más convencionales no es eficiente.

Pharmacological treatment for obesity is very limited; among those available on the market, Semaglutide, a subcutaneous ampoule applied weekly and used in patients with diabetes and obesity, stands out. OBJETIVE: to establish the relationship of Semaglutide as a potential drug for the treatment of obesity. METHOD: descriptive study, mainly focused on the review and analysis of research published in scientific databases of high relevance, restricting only to publications from 2015 onwards (2022) that include as main topic the use of Semaglutide. RESULT: 802 records were identified in the databases, applying the selection criteria 45 articles were identified as potential sources of information, finally 15 articles were selected with highly relevant data for this review, where the dose of the drug for weight reduction was considered, it is observed that the greater the amount of Semaglutide a significant weight reduction is obtained, reaching a mean of 11.82 kg. CONCLUSION: weekly treatment with Semaglutide administered subcutaneously with changes in eating style and physical activity, results in clinically relevant sustained weight loss over time, being able to reach applicability in patients whose treatment by other more conventional methods is not efficient.

Entre os tratamentos existentes no mercado, destaca-se Semaglutide, uma ampola subcutânea que é aplicada semanalmente e utilizada em pacientes com diabetes e obesidade. OBJETIVO: estabelecer a relação do Semaglutide como uma droga potencial para o tratamento da obesidade. METODO: estudo descritivo, focado principalmente na revisão e análise de pesquisas publicadas em bases de dados científicos altamente relevantes, restringindo-se apenas a publicações a partir de 2015 (2022) que incluem o uso do Semaglutide como tema principal. RESULTADOS: 802 registros foram identificados nos bancos de dados, aplicando os critérios de seleção 45 artigos foram identificados como fontes potenciais de informação, finalmente 15 artigos foram selecionados com dados altamente relevantes para esta revisão, onde a dose do medicamento para redução de peso foi considerada, observa-se que quanto maior a quantidade de Semaglutide uma redução de peso significativa é obtida, atingindo uma média de 11,82 kg. CONCLUSAO: o tratamento semanal com Semaglutide administrado subcutaneamente com mudanças na dieta e na atividade física resulta em perda de peso sustentada clinicamente relevante ao longo do tempo, e pode ser aplicável em pacientes cujo tratamento por outros métodos mais convencionais não é eficiente.

[Risk factors for arterial hypertension in the adult population of an urban region of Ecuador]. / Factores de riesgo para hipertensión arterial en población adulta de una región urbana de Ecuador.

Objectives . To determine the risk factors for arterial hypertension (HTN) in the adult resident population of the city of Cuenca, Ecuador Materials and methods A cross-sectional analytical study of adults selected via multistage random sampling who underwent clinical, anthropometric, and laboratory evaluations. The diagnosis of HTN was defined according to the JNC-7 criteria. A multiple logistic regression model was performed Results A total of 318 persons were included. The prevalence of HTN was 25.8% (males: 27.2% vs. females: 24.7%; p = 0.617). In the multiple logistic regression model, the risk factors for HTN were age > 60 years (OR, 8.68; 95% CI, 3.56-21.14; p < 0.001), obesity according to body mass index (OR, 2.36; 95% CI, 1.04-5.70; p = 0.042), high caloric intake (OR, 2.06; 95% CI, 1.01- 4.53; p = 0.044), and family history of HTN (OR, 1.58; 95% CI, 1.02-2.90; p = 0.040) Conclusions The presence of HTN in this population is associated with both intrinsic and environmental factors, which should be considered in routine evaluations to ensure its early identification and control.

Factores de riesgo para hipertensión arterial en población adulta de una región urbana de Ecuador / Risk factors for arterial hypertension in the adult population of an urban region of Ecuador

RESUMEN Objetivos Determinar los factores de riesgo para hipertensión arterial (HTA) en población adulta residente en la ciudadde Cuenca, Ecuador Materiales y métodos Estudio transversal analítico realizado en adultos seleccionados mediante muestreo aleatorio multietápico, a quienes se les realizó evaluación clínica, evaluación antropométrica y de laboratorio. El diagnóstico de HTA fue definido según los criterios del JNC-7. Se realizó un modelo de regresión logística múltiple Resultados Se incluyeron 318 personas. La prevalencia de HTA fue de 25,8% (hombres: 27,2% vs mujeres: 24,7%; p=0,617). En el modelo de regresión logística múltiple, los factores de riesgo para HTA fueron la edad > 60 años (OR 8,68; IC 95%: 3,56-21,14; p<0,001), obesidad según índice de masa corporal (OR 2,36; IC 95%: 1,04-5,70; p=0,042), alto consumo calórico (OR 2,06; IC 95%: 1,01-4,53; p=0,044) y el antecedente familiar de HTA (OR 1,58; IC 95%: 1,02-2,90; p=0,040) Conclusiones La presencia de HTA en esta población se asocia a factores intrínsecos como medioambientales, los cuales deben ser considerados en la evaluación rutinaria para la identificación y control temprano de esta enfermedad.

ABSTRACT Objectives . To determine the risk factors for arterial hypertension (HTN) in the adult resident population of the city of Cuenca, Ecuador Materials and methods A cross-sectional analytical study of adults selected via multistage random sampling who underwent clinical, anthropometric, and laboratory evaluations. The diagnosis of HTN was defined according to the JNC-7 criteria. A multiple logistic regression model was performed Results A total of 318 persons were included. The prevalence of HTN was 25.8% (males: 27.2% vs. females: 24.7%; p = 0.617). In the multiple logistic regression model, the risk factors for HTN were age > 60 years (OR, 8.68; 95% CI, 3.56-21.14; p < 0.001), obesity according to body mass index (OR, 2.36; 95% CI, 1.04-5.70; p = 0.042), high caloric intake (OR, 2.06; 95% CI, 1.01- 4.53; p = 0.044), and family history of HTN (OR, 1.58; 95% CI, 1.02-2.90; p = 0.040) Conclusions The presence of HTN in this population is associated with both intrinsic and environmental factors, which should be considered in routine evaluations to ensure its early identification and control.